SynthesisMolecular diagnosis & therapy2017
Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis.
Synthesis in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review.Archives of gynecology and obstetrics · 2025Pooled it
- Circulating Nucleic Acids in Maternal Plasma and Serum in Pregnancy Complications: Are They Really Useful in Clinical Practice? A Systematic Review.Molecular diagnosis & therapy · 2020Pooled it
- Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events.International journal of molecular sciences · 2025Article
- Prediction of Preeclampsia in Twins Using First Trimester: cffDNA Fraction, PlGF, and MAP.Prenatal diagnosis · 2025Article
- Cell‑free fetal DNA at 11‑13 weeks of gestation is not altered in complicated pregnancies.Biomedical reports · 2024Article
- Early prediction of pre-eclampsia using circulating placental exosomes: Newer insights.The Indian journal of medical research · 2023Review
- Differential immunophenotype of circulating monocytes from pregnant women in response to viral ligands.BMC pregnancy and childbirth · 2023Article
- Analysis of Varying MicroRNAs as a Novel Biomarker for Early Diagnosis of Preeclampsia: A Scoping Systematic Review of the Observational Study.International journal of preventive medicine · 2023Article
- Review
- Results of a Five-Year Experience in First Trimester Preeclampsia Screening.Journal of clinical medicine · 2022Article
- Droplet Digital PCR for Non-Invasive Prenatal Detection of Fetal Single-Gene Point Mutations in Maternal Plasma.International journal of molecular sciences · 2022Article
- Genetic Counseling and Management: The First Study to Report NIPT Findings in a Romanian Population.Medicina (Kaunas, Lithuania) · 2022Article
- Cell-free DNA as a potential biomarker for preeclampsia.Expert review of molecular diagnostics · 2021Article
- Association between Levels of Total Cell-Free DNA and Development of Preeclampsia-A Literature Review.AJP reports · 2021Article
- Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction.Scientific reports · 2020Article
- Cell-Free Fetal DNA Increases Prior to Labor at Term and in a Subset of Preterm Births.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Exosomes-Associated DNA-New Marker in Pregnancy Complications?International journal of molecular sciences · 2019Review
- Cell-Free DNA (cfDNA) Fetal Fraction in Early- and Late-Onset Fetal Growth Restriction.Molecular diagnosis & therapy · 2018Article
- Maternal-fetal cross talk through cell-free fetal DNA, telomere shortening, microchimerism, and inflammation.American journal of reproductive immunology (New York, N.Y. : 1989) · 2018Review
- Cell-free fetal DNA and spontaneous preterm birth.Reproduction (Cambridge, England) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA systematic review and pooled analysis was carried out to estimate whether the increase in the quantity of cell-free fetal DNA (cffDNA) before the onset of pre-eclampsia (PE) can predict the disease using real-time polymerase chain reaction (PCR).
methodA comprehensive literature search of the PubMed, Scopus, and Web of Knowledge databases was conducted to identify relevant studies that included evaluated cffDNA levels in pregnant women before the clinical onset of PE. A simulation model was generated to calculate the detection rate (DR) of cffDNA for PE, and a random variable was generated using the same number of cases and same statistical measurements of central tendency and dispersion as those reported in the papers considered for the analysis. Simulation of the receiver operating characteristic (ROC) curves was also carried out.
resultsFour studies (82 cases and 1315 controls) evaluated cffDNA in early-onset PE, with DRs of 18 and 68.8% at 11-13 and 17-28 weeks, respectively, at a false positive rate of 10%. Nine studies (including two considered for early-onset PE) encompassing 376 cases and 1270 controls were available for the evaluation of 'any PE'. At 11-14 weeks no significant DR was found, while at 15-28 weeks the DR was 37%.
conclusionCffDNA quantification is a marker for predicting the development of both early-onset PE and 'any PE'; however, it can probably only be used from the beginning of the second trimester, otherwise its predictive value is burdened with a DR that is too low or not significant. Due to the heterogeneity and difficulty in interpreting the published data, no conclusion regarding the statistical and clinical relevance, especially for screening 'any PE', can be made at present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.